MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
GBS General and Administrative Expenses 2011-2026 | GBS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses GBS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.88 M | 9.26 M | 8.03 M | 4.92 M | 3.36 M | 2.43 M | 3.55 M | 2.08 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.26 M | 2.08 M | 5.31 M |
Quarterly General and Administrative Expenses GBS
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.34 M | 2.66 M | - | 2.41 M | 1.81 M | 1.95 M | - | 2.43 M | 1.71 M | 2.46 M | - | 1.9 M | 2.25 M | - | 3.7 M | 1.12 M | 1 M | 1.33 M | 2.34 M | 1.01 M | 671 K | 521 K | 671 K | 53.8 K | 972 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.7 M | 53.8 K | 1.68 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M |  USA |
 |
Bruker Corporation
BRKR
|
894 M | $ 39.08 | -1.83 % | $ 5.82 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | USA |
 |
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | USA |
 |
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
163 M | $ 7.79 | 3.73 % | $ 559 M |  Israel |
 |
FONAR Corporation
FONR
|
23.5 M | $ 18.49 | -0.38 % | $ 121 M | USA |
 |
AdaptHealth Corp.
AHCO
|
382 M | $ 9.41 | -2.39 % | $ 1.27 B | USA |
 |
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
132 M | $ 43.34 | -5.35 % | $ 1.35 B | USA |
 |
IRIDEX Corporation
IRIX
|
8.75 M | $ 1.45 | 2.84 % | $ 23.4 M | USA |
 |
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | USA |
 |
IRadimed Corporation
IRMD
|
15.9 M | $ 104.65 | 0.88 % | $ 1.33 B | USA |
 |
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
44.6 M | $ 29.78 | -2.84 % | $ 1.37 B | USA |
 |
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.18 | -3.05 % | $ 110 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Accuray Incorporated
ARAY
|
47.9 M | $ 0.52 | -5.19 % | $ 53.4 M | USA |
 |
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | USA |
 |
Pulmonx Corporation
LUNG
|
102 M | $ 1.53 | - | $ 59.8 M | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
Medigus Ltd.
MDGS
|
9.96 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Medtronic PLC
MDT
|
10.8 B | $ 96.73 | -1.38 % | $ 124 B | USA |
 |
Cytosorbents Corporation
CTSO
|
35 M | $ 0.79 | 5.78 % | $ 43 M | USA |
 |
Align Technology
ALGN
|
1.76 B | $ 182.92 | -3.23 % | $ 13.7 B | USA |
 |
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | USA |
 |
Inari Medical
NARI
|
293 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
39.8 M | $ 3.73 | -3.37 % | $ 790 M | USA |
 |
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | USA |
 |
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.96 | -3.54 % | $ 148 M |  France |
 |
Abbott Laboratories
ABT
|
12.3 B | $ 113.53 | -0.49 % | $ 198 B | USA |
 |
NuVasive
NUVA
|
634 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
310 M | - | - | $ 217 M | USA |
 |
Orthofix Medical
OFIX
|
554 M | $ 13.02 | -2.62 % | $ 516 M |  Curacao |
 |
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.89 B | $ 73.88 | -3.07 % | $ 109 B | USA |
 |
PAVmed
PAVM
|
30.9 M | $ 9.94 | -0.4 % | $ 71.9 M | USA |
 |
Penumbra
PEN
|
663 M | $ 340.23 | -0.61 % | $ 13.2 B | USA |